Published in J Lipid Res on September 14, 2010
Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis (2012) 1.50
Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J Lipid Res (2010) 1.17
Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem (2013) 0.98
Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. J Am Chem Soc (2013) 0.94
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res (2014) 0.92
An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS One (2013) 0.89
In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J Lipid Res (2014) 0.87
High-density lipoprotein mimetics: promises and challenges. Biochem J (2015) 0.76
Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats. Biochem Biophys Res Commun (2013) 0.75
Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (1992) 11.83
Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol (1983) 10.95
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91
Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc (2004) 2.33
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 2.27
Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci U S A (2007) 1.98
Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 1.89
A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res (2000) 1.83
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res (2007) 1.65
A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 1.53
Precise scanning calorimeter for studying thermal properties of biological macromolecules in dilute solution. Anal Biochem (1995) 1.51
Interactions of synthetic peptide analogs of the class A amphipathic helix with lipids. Evidence for the snorkel hypothesis. J Biol Chem (1994) 1.39
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res (2009) 1.37
Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest (1989) 1.35
Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest (1994) 1.26
Does arginine remain protonated in the lipid membrane? Insights from microscopic pKa calculations. Biophys J (2008) 1.18
Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest (1992) 1.16
ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem (2006) 1.16
Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem (2004) 1.15
Roles of arginine and lysine residues in the translocation of a cell-penetrating peptide from (13)C, (31)P, and (19)F solid-state NMR. Biochemistry (2009) 1.15
Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation (2005) 1.14
Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep (2009) 1.13
Synthetic peptide analogs of apolipoproteins. Methods Enzymol (1986) 1.13
The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry (2000) 1.10
Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis (2003) 1.03
Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis (2009) 1.02
Reciprocal effects of apolipoprotein and lytic peptide analogs on membranes. Cross-sectional molecular shapes of amphipathic alpha helixes control membrane stability. J Biol Chem (1993) 0.97
Detecting the presence of membrane domains using DSC. Biophys Chem (2006) 0.96
An apolipoprotein AI mimetic peptide: membrane interactions and the role of cholesterol. Biochemistry (2004) 0.92
Counterion-mediated membrane penetration: cationic cell-penetrating peptides overcome Born energy barrier by ion-pairing with phospholipids. Biochim Biophys Acta (2007) 0.90
Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids. Biochim Biophys Acta (2009) 0.83
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides. Proc Natl Acad Sci U S A (1989) 3.94
The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res (1992) 3.74
Amphipathic helix motif: classes and properties. Proteins (1990) 3.52
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 2.62
Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet (2007) 2.51
The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A (2004) 2.39
Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol (2005) 2.33
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 2.27
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res (2000) 2.22
Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis (2012) 2.19
Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. J Biol Chem (2003) 2.12
Mimicry of antimicrobial host-defense peptides by random copolymers. J Am Chem Soc (2007) 2.12
Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 2.11
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res (2000) 2.05
D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 1.99
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res (2007) 1.96
Concern Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci U S A (2006) 1.92
Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 1.89
The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem (1994) 1.89
A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res (2000) 1.83
Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta (2001) 1.80
Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol (2006) 1.80
The role of dysfunctional HDL in atherosclerosis. J Lipid Res (2008) 1.73
Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A (2010) 1.71
Membrane fusion. Chem Rev (2003) 1.69
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res (2007) 1.65
Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim Biophys Acta (2008) 1.58
Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol (1996) 1.55
Computer programs to identify and classify amphipathic alpha helical domains. J Lipid Res (1992) 1.54
Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J Biol Chem (1992) 1.53
A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 1.53
Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins. J Biol Chem (1993) 1.50
Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis (2012) 1.50
Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology (2011) 1.49
Regulation and functions of diacylglycerol kinases. Chem Rev (2011) 1.48
Mechanisms for the modulation of membrane bilayer properties by amphipathic helical peptides. Biopolymers (1995) 1.48
Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (Ceragenins). Biochim Biophys Acta (2007) 1.47
Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol (2009) 1.40
The apoptotic protein tBid promotes leakage by altering membrane curvature. J Biol Chem (2002) 1.40
Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine. Lab Invest (2009) 1.40
Interactions of synthetic peptide analogs of the class A amphipathic helix with lipids. Evidence for the snorkel hypothesis. J Biol Chem (1994) 1.39
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res (2009) 1.37
Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation (2002) 1.37
Dual mechanism of bacterial lethality for a cationic sequence-random copolymer that mimics host-defense antimicrobial peptides. J Mol Biol (2008) 1.37
Tocopherols and tocotrienols in membranes: a critical review. Free Radic Biol Med (2007) 1.37
Double belt structure of discoidal high density lipoproteins: molecular basis for size heterogeneity. J Mol Biol (2004) 1.36
Juxtamembrane protein segments that contribute to recruitment of cholesterol into domains. Biochemistry (2006) 1.36
Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res (2005) 1.35
Correlated fluorescence-atomic force microscopy of membrane domains: structure of fluorescence probes determines lipid localization. Biophys J (2005) 1.33
Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med (2006) 1.33
Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res (2005) 1.30
Bacterial membrane lipids in the action of antimicrobial agents. J Pept Sci (2010) 1.30
Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides. Biochem Cell Biol (2002) 1.28
Bioactivity of peptide analogs of the neutrophil chemoattractant, N-acetyl-proline-glycine-proline. Invest Ophthalmol Vis Sci (1999) 1.28
Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J Lipid Res (2002) 1.27
Tryptophan-rich antimicrobial peptides: comparative properties and membrane interactions. Biochem Cell Biol (2002) 1.26
Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest (1994) 1.26
Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci U S A (2010) 1.25
Truncation of the amino terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation. Biochemistry (1997) 1.25
Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry (1995) 1.25
Lipid segregation explains selective toxicity of a series of fragments derived from the human cathelicidin LL-37. Antimicrob Agents Chemother (2009) 1.24
Probing the "charge cluster mechanism" in amphipathic helical cationic antimicrobial peptides. Biochemistry (2010) 1.24